When some patients leave hospital they can need extra support taking their prescribed medicines. This may be because their medicines have changed or they need a bit of help taking their medicines safely and effectively.
The transfer of care process is associated with an increased risk of adverse effects. 30-70% of patients experience unintentional changes to their treatment or an error is made because of a miscommunication.
This is what the Transfers of Care Around Medicine (TCAM) project aims to address.
When patients discharged from hospital are identified as needing extra support, they are referred through a safe and secure digital platform for advice from their local community pharmacist.
Original work in the North East showed that patients who see their community pharmacist after they’ve been in hospital are less likely to be readmitted and, if they are, will experience a shorter stay.
Many AHSNs, including Wessex and the West of England, have worked with trusts and Local Pharmaceutical Committees to help set up a secure electronic interface between the hospital IT systems and PharmOutcomes, the community pharmacy system used in their area. This has further enhanced TCAM by providing patient data quickly and seamlessly to their community pharmacist.
Wessex AHSN developed an awareness campaign to encourage people to seek help with their medicines, featuring a character called Mo in a series of animated films and accompanying poster resources for pharmacies. The films have been viewed almost 64,000 times.
Through our national implementation of TCAM in 2018-2020, each AHSN will support their local trusts to establish a TCAM pathway. This will enable all suitable patients to be referred to their community pharmacy or GP pharmacist where appropriate.
AHSNs have high level targets to improve the number of hospitals and discharges implementing TCAM referrals.
Nationally, with rapid adoption across all 15 AHSNs, TCAM has the potential to save £13.8 million, reduce length of stay by 56,704 days and achieve 1,004 fewer readmissions in 2018-19. In 2019-20, savings of £28.8 million are projected, based on a reduction in length of stay of 113,406 days and 2,007 fewer readmissions.
For more information, please contact Paul Cordy, Interim Head of Atrial Fibrillation and Medicines Optimisation Programmes